TransMedics Group (FRA:8T8) EBIT per Share : €1.32 (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is TransMedics Group EBIT per Share?

TransMedics Group's EBIT per Share for the three months ended in Dec. 2024 was €0.29. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €1.32.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for TransMedics Group's EBIT per Share or its related term are showing as below:

During the past 9 years, the highest 3-Year average EBIT per Share Growth Rate of TransMedics Group was 20.10% per year. The lowest was -10.80% per year. And the median was 6.10% per year.

FRA:8T8's 3-Year EBIT Growth Rate is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 5.25
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

TransMedics Group's EBIT for the three months ended in Dec. 2024 was €10.1 Mil.

TransMedics Group EBIT per Share Historical Data

The historical data trend for TransMedics Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TransMedics Group EBIT per Share Chart

TransMedics Group Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

-0.82

-1.29

-1.04

-0.45

1.36

TransMedics Group Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial															0.21	0.42	0.42	0.20	0.29

TransMedics Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

TransMedics Group's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	47.93	/	35.217
=	1.36

TransMedics Group's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	10.085	/	35.211
=	0.29

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.32

TransMedics Group (FRA:8T8) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

TransMedics Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of TransMedics Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

TransMedics Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TransMedics Group Inc (FRA:8T8) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

TMDX:USA TMDX:Germany

Address

200 Minuteman Road, Andover, MA, USA, 01810

Website

https://www.transmedics.com

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group Headlines

No Headlines